Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Hanna, David B ^a,b   Buchacz, Kate ^c   Gebo, Kelly A ^a   Hessol, Nancy A ^d   Horberg, Michael A ^e   Jacobson, Lisa P ^a   Kirk, Gregory D ^a   Kitahata, Mari M ^f   Todd Korthuis, P ^g   Moore, Richard D ^a   Napravnik, Sonia ^h   Patel, Pragna ^c   Silverberg, Michael J ⁱ   Sterling, Timothy R ^j   Willig, James H ^k   Collier, Ann ^d   Samji, Hasina ^l   Thorne, Jennifer E ^a   Althoff, Keri N ^a   Martin, Jeffrey N ^d   Rodriguez, Benigno ^m   Stuart, Elizabeth A ^a   Gange, Stephen J ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Mid Atlantic Permanente Research Institute   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^m CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CANADA; FEMALE; GOVERNMENT PROGRAMS; HEALTHCARE FINANCING; HUMANS; MALE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84894146769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078952     Document Type: Article

References (56)

1. Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Available: http://www.whitehouse.gov/administration/eop/onap/nhas. Accessed 15 Jul 2010.
2. Centers for Disease Control and Prevention (2011) Vital signs: HIV prevention through care and treatment - United States. MMWR Morb Mortal Wkly Rep 60(47): 1618-23.
3. Palella FJ, Baker RK, Buchacz K, Chmiel JS, Tedaldi EM, et al. (2011) Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 25(15): 1865-76.
4. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, et al.(1999) Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA 281(24): 2305-15. (Pubitemid 29289823)
5. Yehia BR, Fleishman JA, Hicks PL, Ridore M, Moore RD, et al. (2010) Inpatient health services utilization among HIV-infected adult patients in care 2002-2007. J Acquir Immune Defic Syndr 53(3): 397-404.
6. Chander G, Himelhoch S, Fleishman JA, Hellinger J, Gaist P, et al. (2009) HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care 21(5): 655-63.
7. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, et al. (2013) Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis 56(8): 1174-82.
8. Moore RD, Keruly JC, Bartlett JG (2012) Improvement in the health of HIV-infected persons in care: reducing disparities. Clin Infect Dis 55(9): 1242-51.
9. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, et al. (2011) Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 203(4): 442-51.
10. Hellinger FJ, Fleishman JA (2011) Location, race, and hospital care for AIDS patients: An analysis of 10 states. Inquiry 38(3): 319-30.
11. Fleishman JA, Hellinger FH (2003) Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study. J Acquir Immune Defic Syndr 34(1): 102-10. (Pubitemid 37100119)
12. Hanna DB, Selik RM, Tang T, Gange SJ (2012) Disparities among US states in HIV-related mortality in persons with HIV infection, 2001-2007. AIDS 26(1): 95-103.
13. Blair JM, McNaghten AD, Frazier EL, Skarbinski J, Huang P, et al. (2011) Clinical and behavioral characteristics of adults receiving medical care for HIV infection - Medical Monitoring Project, United States, 2007. MMWR Surveill Summ 60(11): 1-20.
14. National Alliance of State and Territorial AIDS Directors. National ADAP Monitoring Project Annual Report. Available: http://www.nastad.org/Docs/020035- 2011%20NASTAD%20National%20ADAP%20Monitoring%20Project%20Annual%20Report.pdf. Accessed 8 Dec 2011.
15. National Alliance of State and Territorial AIDS Directors. National ADAP Monitoring Project Annual Report. Available: http://www.nastad.org/Docs/020035- 2011%20NASTAD%20National%20ADAP%20Monitoring%20Project%20Annual%20Report.pdf. Accessed 8 Dec 2011.
16. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immuno deficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338(13): 853-60. (Pubitemid 28135961)
17. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360(18): 1815-26.
18. National Alliance of State and Territorial AIDS Directors. National ADAP Monitoring Project Annual Report, Module One. Available: http://www.nastad.org/ Docs/081741-Module%20One%20- %20National%20ADAP%20Monitoring%20Project%20Annual%20Report%20- %20January%202012.pdf. Accessed 9 May 2012.
19. Pinkerton SD, Kibicho J, Galletly CL (2013) Is the US AIDS drug assistance program cost-effective? AIDS Behav 17(1): 1-4.
20. Johri M, David Paltiel A, Goldie SJ, Freedberg KA (2002) State AIDS Drug Assistance Programs: Equity and efficiency in an era of rapidly changing treatment standards. Med Care 40(5): 429-41.
21. Linas BP, Zheng H, Losina E, Rockwell A, Walensky RP, et al. (2006) Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis 43(10): 1357-64. (Pubitemid 44706466)
22. Linas BP, Losina E, Rockwell A, Walensky RP, Cranston K, et al. (2009) Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr 51(5): 513-21.
23. Bassett IV, Farel C, Szmuilowicz ED, Walensky RP (2008) HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis 47(5): 695-701.
24. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, et al.(2011) Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One 6(4): e18462.
25. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD (2013) Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS ePub 13 Jun 2013.
26. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, et al. (2007) Cohort profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 36(2): 294-301. (Pubitemid 47064328)
27. Panel on Clinical Practices for Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. Available: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL02052001009.pdf. Accessed 15 Aug 2011.
28. Relucio K, Holodniy M (2002) HIV-1 RNA and viral load. Clin Lab Med 22(3):593-610. (Pubitemid 35014991)
29. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, et al. (2013)Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis 56(8): 1174-82.
30. Lau B, Gange SJ, Moore RD (2007) Interval and clinical cohort studies:epidemiological issues. AIDS Res Hum Retroviruses 23(6): 769-76. (Pubitemid 47047915)
31. U.S. Census Bureau. Population estimates. Available: http://www.census. gov/popest/estimates.html. Accessed 31 Jan 2010.
32. Henry J. Kaiser Family Foundation. statehealthfacts.org: HIV/AIDS. Available:http://www.statehealthfacts.org/comparecat.jsp?cat =11&rgn= 6&rgn = 1. Accessed1 Feb 2013.
33. U.S. Census Bureau. Current Population Survey (CPS). Available: http://www.census.gov/cps/data/. Accessed 31 Jan 2010.
34. Ho D, Imai K, King G, Stuart E (2007) Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Pol Analysis 15: 199-236.
35. Crump RK, Hotz VJ, Imbens GW, Mitnik O. Moving the goalposts: Addressing limited overlap in estimation of average treatment effects by changing the estimand (working paper, Univ. California-Berkeley). Available: http://elsa.berkeley.edu/users/webfac/mcfadden/e242-s05/imbens.pdf. Accessed 26 Mar 2012.
36. Reif S, Whetten K, Wilson E. HIV/AIDS epidemic in the South reaches crisis proportions in last decade. Available: http://southernaids.files. wordpress.com/2011/10/research-report-final-revised10-26-121.pdf. Accessed 12 Dec 2011.
37. Walensky RP, Paltiel AD, Freedberg KA (2002) AIDS Drug Assistance Programs: Highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis 35(5): 606-10.
38. Human Rights Watch. Southern Exposure: Human Rights and HIV in the Southern United States. Available: http://www.hrw.org/node/94476. Accessed 17 Apr 2012.
39. Martin EG, Keenan PS (2011) Sticky dollars: Inertia in the evolution of federal allocations for HIV care through the Ryan White HIV/AIDS Program. Publius4(1): 101-25.
40. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, et al. (2006) Results ofmultivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.Am J Epidemiol 163(3): 262-70. (Pubitemid 43145754)
41. Blackstock OJ, Wang KH, Fiellin DA (2011) State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. J Gen Intern Med 26(12): 1426-33.
42. Yi T, Cocohoba J, Cohen M, Anastos K, DeHovitz JA, et al. (2011) The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women.J Acquir Immune Defic Syndr 56(3): 253-62.
43. Martin EG, Barry CL (2011) The adoption of mental health drugs on state AIDS drug assistance program formularies. Am J Public Health 101(6): 1103-9.
44. Cheever LW, Kresina TF, Cajina A, Lubran R (2011) A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr 56 Suppl 1: S3-6.
45. Godwin NC, Willig JH, Nevin CR, Lin HY, Allison J, et al. (2011)Under utilization of the AIDS Drug Assistance Program: associated factors and policy implications. Health Serv Res 46(3): 982-95.
46. Carrico AW, Bangsberg DR, Weiser SD, Chartier M, Dilworth SE, et al. (2011)Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS 25(8): 1113-8.
47. Crowley JS, Kates J. Updating the Ryan White HIV/AIDS Program for a New Era: Key Issues and Questions for the Future. Available: http://www.kff.org/ hivaids/upload/8431.pdf. Accessed 1 Apr 2013.
48. Althoff KN, Buchacz K, Hall IH, Zhang J, Hanna DB, et al. (2012) U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med 157(5): 325-35.
49. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL002111.pdf. Accessed 22 Dec 2009.
50. Committee to Review Data Systems for Monitoring HIV Care, Board on Population Health and Public Health Practice (2012) Monitoring HIV Care in the United States: Indicators and Data Systems. Washington: Natl Academies Press.
51. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ (2011)The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 52(6):793-800.
52. Centers for Disease Control and Prevention (2011) Results of the Expanded HIV Testing Initiative-25 jurisdictions, United States, 2007-2010. MMWR Morb Mortal Wkly Rep 60(24): 805-10.
53. U.S. Department of Health and Human Services. Overview of the uninsured in the United States: A summary of the 2011 Current Population Survey.Available: http://aspe.hhs.gov/health/reports/2011/CPSHealthIns2011/ib.pdf. Accessed 18 Apr 2012.
54. Martin EG, Schackman BR (2012) What does US health reform mean for HIV clinical care? J Acquir Immune Defic Syndr 60(1): 72-6.
55. McManus KA, Engelhard CL, Dillingham R (2013) Current challenges to the United States' AIDS Drug Assistance Program and possible implications of the Affordable Care Act. AIDS Res Treat 2013: 350169.
56. Martin EG, Meehan T, Schackman BR (2013) AIDS Drug Assistance Programs: Managers confront uncertainty and need to adapt as the Affordable Care Act kicks in. Health Aff (Millwood) 32(6): 1063-71.